Journal of Trauma and Injury

The Korean Society of Traumatology (대한외상학회)
권호 표지

Serious Bleeding Complication Due to the Use of Low-molecular-weight heparin to treat a Traumatic Patient with Acute Renal Failure

급성신부전이 발생한 중증 외상 환자에서 저분자량헤파린 투여 후 발생한 심각한 출혈 합병증

  • Kyoung, Kyu-Hyouck (Department of Surgery, Inje university college of medicine, Haeundae Paik Hospital) ;
  • Kim, Woon-Won (Department of Surgery, Inje university college of medicine, Haeundae Paik Hospital) ;
  • Park, Sung-Jin (Department of Surgery, Inje university college of medicine, Haeundae Paik Hospital) ;
  • Kim, Ki-Hoon (Department of Surgery, Inje university college of medicine, Haeundae Paik Hospital) ;
  • Kim, Jin-Soo (Department of Surgery, Inje university college of medicine, Haeundae Paik Hospital) ;
  • Park, Jong-Kwon (Department of Surgery, Inje university college of medicine, Haeundae Paik Hospital)
  • 경규혁 (인제대학교 의과대학 해운대백병원 외과) ;
  • 김운원 (인제대학교 의과대학 해운대백병원 외과) ;
  • 박성진 (인제대학교 의과대학 해운대백병원 외과) ;
  • 김기훈 (인제대학교 의과대학 해운대백병원 외과) ;
  • 김진수 (인제대학교 의과대학 해운대백병원 외과) ;
  • 박종권 (인제대학교 의과대학 해운대백병원 외과)
  • Received : 2011.10.21
  • Accepted : 2011.11.02
  • Published : 2011.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Trauma is an important risk factor for a pulmonary thromboembolism, and anticoagulation is essential to prevent deep vein thrombosis (DVT) in patients with trauma. Low-molecular-weight heparin (LMWH) is excreted in the kidney; therefore, using LMWH in patients with renal insufficiency may increase the risk of bleeding complication. The following case describes a 55-year-old traffic accident victim who had massive bleeding and underwent a laparotomy for bleeding control. The patient had acute renal failure, and enoxaparin was administered for the prophylaxis of DVT. Although the patient suffered from serious complications such as pericardial hematoma, the patient recovered without sequellae and was discharged at day 84.

Keywords

References

  1. Ho KM, Burrell M, Rao S, Baker R. Incidence and risk factors for fatal pulmonary embolism after major trauma: a nested cohort study. Br J Anaesth 2010;105: 596-602. https://doi.org/10.1093/bja/aeq254
  2. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994;331:1601-1606. https://doi.org/10.1056/NEJM199412153312401
  3. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S. https://doi.org/10.1378/chest.08-0656
  4. Geerts W, Selby R. Prevention of venous thromboembolism in the ICU. Chest 2003;124:357S-363S. https://doi.org/10.1378/chest.124.6_suppl.357S
  5. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701-707. https://doi.org/10.1056/NEJM199609053351003
  6. Morris RJ, Woodcock JP. Intermittent pneumatic compression or graduated compression stockings for deep vein thrombosis prophylaxis? A systematic review of direct clinical comparisons. Ann Surg 2010;251:393-396. https://doi.org/10.1097/SLA.0b013e3181b5d61c
  7. De A, Roy P, Garg VK, Pandey NK. Low-molecularweight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery. Blood Coagul Fibrinolysis. 2010;21:57-61. https://doi.org/10.1097/MBC.0b013e3283333505
  8. Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Anesth Analg 1997;85:874-885. https://doi.org/10.1213/00000539-199710000-00031
  9. Rutherford EJ, Schooler WG, Sredzienski E, Abrams JE, Skeete DA. Optimal dose of enoxaparin in critically ill trauma and surgical patients. J Trauma 2005;58: 1167-1170. https://doi.org/10.1097/01.TA.0000172292.68687.44
  10. Robinson S, Zincuk A, Strøm T, Larsen TB, Rasmussen B, Toft P. Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Crit Care 2010;14:R41. https://doi.org/10.1186/cc8924
  11. Vivino G, Antonelli M, Moro ML, Cottini F, Conti G, Bufi M, et al. Risk factors for acute renal failure in trauma patients. Intensive Care Med 1998;24:808-814. https://doi.org/10.1007/s001340050670
  12. Gomes E, Antunes R, Dias C, Araujo R, Costa-Pereira A. Acute kidney injury in severe trauma assessed by RIFLE criteria: a common feature without implications on mortality? Scand J Trauma Resusc Emerg Med 2010;18:1. https://doi.org/10.1186/1757-7241-18-1
  13. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000;20:771-775. https://doi.org/10.1592/phco.20.9.771.35210
  14. Brophy DF, Martin EJ, Gehr TW, Carr ME Jr. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. Am J Kidney Dis 2004;44:270-277. https://doi.org/10.1053/j.ajkd.2004.04.032
  15. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225-231. https://doi.org/10.1016/S0049-3848(02)00031-2
  16. Han SJ, Kim HS, Kim KI, Whang SM, Hong KS, Lee WK, et al. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. J Korean Med Sci 2011;26:945-950. https://doi.org/10.3346/jkms.2011.26.7.945
  17. Yang JW, Han BG, Kim BR, Lee YH, Kim YS, Yu JM, et al. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage. Ren Fail 2009;31:668-675. https://doi.org/10.3109/08860220903180616